Topical use of sucralfate in epithelial wound healing: Clinical evidence and molecular mechanisms of action

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 4, Issue 1, 2010, Pages 25-36

  Masuelli, Laura ^a   Tumino, Giovanni ^b   Turriziani, Mario ^b   Modesti, Andrea ^c   Bei, Roberto ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Epithelial wound; Growth factors; Healing; Inflammation; Sucralfate; Topical

Indexed keywords

DERMATOLOGICAL AGENT; POVIDONE IODINE; SODIUM SUCROSE OCTASULFATE; SUCRALFATE; SULFADIAZINE SILVER; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR; MATRIX METALLOPROTEINASE;

ANTIBACTERIAL ACTIVITY; APHTHOUS STOMATITIS; ARTICLE; BURN; CELL PROLIFERATION; CLINICAL TRIAL; DERMATITIS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EPITHELIUM; GRANULATION TISSUE; HEMOSTASIS; HUMAN; INFLAMMATION; LEG ULCER; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; SKIN INJURY; ULCER HEALING; VAGINAL ULCER; WOUND; WOUND CONTRACTION; WOUND HEALING; ANGIOGENESIS; ANIMAL; DRUG EFFECT; METABOLISM; PATENT; PATHOLOGY; REVIEW; ULCER;

ANIMALS; DERMATITIS; EPITHELIUM; FIBROBLAST GROWTH FACTORS; GRANULATION TISSUE; HUMANS; MATRIX METALLOPROTEINASES; NEOVASCULARIZATION, PHYSIOLOGIC; PATENTS AS TOPIC; SUCRALFATE; ULCER; WOUND HEALING;

EID: 77953102462     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221310789895649     Document Type: Article

References (131)

1. Kiritsy CP, Lynch AB, Lynch SE. Role of growth factors in cutaneous wound healing: A review. Crit Rev Oral Biol Med 1993; 4(5): 729-760.
2. Toriseva M, Kähäri VM. Proteinases in cutaneous wound healing. Cell Mol Life Sci 2009; 66(2): 203-224.
3. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005; 366(9498): 1736-1743.
4. Braund R, Hook S, Medlicott NJ. The role of topical growth factors in chronic wounds. Curr Drug Deliv 2007; 4(3): 195-204.
5. Li J, Chen J, Kirsner R. Pathophysiology of acute wound healing. Clin Dermatol 2007; 25(1): 9-18.
6. Gibran NS, Boyce S, Greenhalgh DG. Cutaneous wound healing. J Burn Care Res 2007; 28(4): 577-579.
7. Strukova S. Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation-dependent thrombosis. Front Biosci 2006; 11(1): 59-80.
8. Clark RAF, Ghosh K, Tonnesen MG. Tissue engineering for cutaneous wounds. J Invest Dermatol 2007; 127:1018-1029.
9. Beanes SR, Dang C, Soo C, Ting K. The phases of cutaneous wound healing. Exp Rev Mol Med 2003; 5(8): 1-22.
10. Sica A, Allavena P, Mantovani A. Cancer related inflammation: The macrophage connection. Cancer Lett 2008; 267(2): 204-215.
11. Mantovani A, Pierotti MA. Cancer and inflammation: A complex relationship. Cancer Lett 2008; 267(2): 180-181.
12. Bei R, Masuelli L, Palumbo C, Modesti M, Modesti A. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth. Cancer Lett 2009; 281(1): 8-23.
13. Bei R, Masuelli L, Palumbo C, Tresoldi I, Scardino A, Modesti A. Long-lasting tissue inflammatory processes trigger autoimmune responses to extracellular matrix molecules. Int Rev Immunol 2008; 27(3): 137-175.
14. Martins PS, Kallas EG, Neto MC, Dalboni MA, Blecher S, Salomão R. Upregulation of reactive oxygen species generation and phagocytosis, and increased apoptosis in human neutrophils during severe sepsis and septic shock. Shock 2003; 20(3): 208-212.
15. Manzo A, Caporali R, Montecucco C, Pitzalis C. Role of chemokines and chemokine receptors in regulating specific leukocyte trafficking in the immune/inflammatory response. Clin Exp Rheumatol 2003; 21 (4): 501-508.
16. Volkin DB, Verticelli AM, Marfia KE, Burke CJ, Mach H, Middaugh CR. Sucralfate and soluble sucrose octasulfate bind and stabilize acidic fibroblast growth factor. Biochim Biophys Acta 1993; 1203(1): 18-26.
17. Rees WD. Mechanisms of gastroduodenal protection by sucralfate. Am J Med 1991; 91(2A): 58S-63S.
18. Szabo S. The mode of action of sucralfate: The 1 x 1 x 1 mechanism of action. Scand J Gastroenterol 1991; 185 (Suppl): 7-12.
19. Coleridge-Smith PD. Leg ulcer treatment. J Vasc Surg 2009; 49(3): 804-808.
20. Tsakayannis D, Li WW, Razvi S, Spirito N. Sucralfate and chronic venous stasis ulcers. Lancet 1994; 343(8894): 424-425.
21. Tumino G, Masuelli L, Bei R, Simonelli L, Santoro A, Francipane S. Topical treatment of chronic venous ulcers with sucralfate: A placebo controlled randomized study. Int J Mol Med 2008; 22(1): 17-23.
22. Hayashi AH, Lau HY, Gillis DA. Topical sucralfate: Effective therapy for the management of resistant peristomal and perineal excoriation. J Pediatr Surg 1991; 26(11): 1279-1281.
23. Lyon CC, Stapleton M, Smith AJ, Griffiths CE, Beck MH. Topical sucralfate in the management of peristomal skin disease: An open study. Clin Exp Dermatol 2000; 25(8): 584-588.
24. Mantoo S, Raina VK. Topical sucralfate: Role in the prevention and healing of skin excoriations around enterostomas, gastro-intestinal fistulas and perineal region. J Indian Ass Ped Surg 1997; 2(4): 126-129.
25. Markham T, Kennedy F, Collins P. Topical sucralfate for erosive irritant diaper dermatitis. Arch Dermatol 2000; 136(10): 1199-1200.
26. Burkhart CG, Black C, Burkhart CN. A topical application containing sucralfate, zinc oxide and ketoconazole provides high patients satisfaction in the treatment of intertrigo. Open Dermatol J 2009; 3: 11-13.
27. Lentz SS, Barrett RJ, Homesley HD. Topical sucralfate in the treatment of vaginal ulceration. Obstet Gynecol 1993; 81(5(Pt 2)): 869-871.
28. Alpsoy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: A randomized, placebo-controlled, double-blind study. Arch Dermatol 1999; 135(5): 529-532.
29. Lin P, Liang G. Behçet disease: Recommendation for clinical management of mucocutaneous lesions. J Clin Rheumatol 2006; 12(6): 282-286.
30. Rattan J, Schneider M, Arber N, Gorsky M, Dayan D. Sucralfate suspension as a treatment of recurrent aphthous stomatitis. J Intern Med 1994; 236(3): 341-343.
31. Altenburg A, Abdel-Naser MB, Seeber H, Abdallah M, Zouboulis CC. Practical aspects of management of recurrent aphthous stomatitis. J Eur Acad Dermatol Venereol 2007; 21(8): 1019-1026.
32. Altenburg A, Zouboulis CC. Current concepts in the treatment of recurrent aphthous stomatitis. Skin Ther Lett 2008; 13(7): 1-4.
33. Gupta PJ, Heda PS, Kalaskar S, Tamaskar VP. Topical sucralfate decreases pain after hemorrhoidectomy and improves healing: A randomized, blinded, controlled study. Dis Colon Rectum 2008; 51(2): 231-234.
34. Banati A, Chowdhury SR, Mazumder S. Topical use of Sucralfate Cream in second and third degree burns. Burns 2001; 27(5): 465-469.
35. Olascoaga A, Vilar-Compte D, Poitevin-Chacón A, Contreras-Ruiz J. Wound healing in radiated skin: Pathophysiology and treatment options. Int Wound J 2008; 5(2): 246-257.
36. Keefe DM, Schubert MM, Elting LS, et al. Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109(5): 820-831.
37. Maiche A, Isokangas OP, Gröhn P. Skin protection by sucralfate cream during electron beam therapy. Acta Oncol 1994; 33(2): 201-203.
38. Cengiz M, Ozyar E, Oztürk D, Akyol F, Atahan IL, Hayran M. Sucralfate in the prevention of radiation-induced oral mucositis. J Clin Gastroenterol 1999; 28(1): 40-43.
39. Etiz D, Erkal HS, Serin M, et al. Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies. Oral Oncol 2000; 36(1): 116-120.
40. Evensen JF, Bjordal K, Jacobsen AB, Løkkevik E, Tausjø JE. Effects of Na-sucrose octasulfate on skin and mucosa reactions during radiotherapy of head and neck cancers--a randomized prospective study. Acta Oncol 2001; 40(6): 751-755.
41. Epstein JB, Wong FL. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. Int J Radiat Oncol Biol Phys 1994; 28(3): 693-698.
42. Lievens Y, Haustermans K, Van den Weyngaert D, et al. Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiother Oncol 1998; 47(2): 149-153.
43. Makkonen TA, Boström P, Vilja P, Joensuu H. Sucralfate mouth washing in the prevention of radiation-induced mucositis: A placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 1994; 30(1): 177-182.
44. Sur RK, Kochhar R, Singh DP. Oral sucralfate in acute radiation oesophagitis. Acta Oncol 1994; 33(1): 61-63.
45. McGinnis WL, Loprinzi CL, Buskirk SJ, et al. Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis. J Clin Oncol 1997; 15(3):1239-1243.
46. Wells M, Macmillan M, Raab G, et al. Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiother Oncol 2004; 73(2): 153-162.
47. Kochhar R, Mehta SK, Aggarwal R, Dhar A, Patel F. Sucralfate enema in ulcerative rectosigmoid lesions. Dis Colon Rectum 1990; 33(1): 49-51.
48. Kochhar R, Patel F, Dhar A, et al. Radiation-induced proctosig-moiditis. Prospective, randomized, double-blind controlled trial of oral sulfasalazine plus rectal steroids versus rectal sucralfate. Dig Dis Sci 1991; 36(1): 103-107.
49. Kochhar R, Sriram PV, Sharma SC, Goel RC, Patel F. Natural history of late radiation proctosigmoiditis treated with topical sucralfate suspension. Dig Dis Sci 1999; 44(5): 973-978.
50. Kochhar R, Sharma SC, Gupta BB, Mehta SK. Rectal sucralfate in radiation proctitis. Lancet 1988; 2(8607): 400.
51. Leiper K, Morris AI. Treatment of radiation proctitis. Clin Oncol (R Coll Radiol) 2007; 19(9): 724-729.
52. Folkman J, Szabo S, Stovroff M, McNeil P, Li W, Shing Y. Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann Surg 1991; 214(4): 414-425.
53. Yeh BK, Eliseenkova AV, Plotnikov AN, et al. Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate. Mol Cell Biol 2002; 22(20): 7184-7192.
54. Louw JA, Modlin IM, Tang L, Young GO, Lucke W, Marks IN. Changes in mucosal levels of transforming growth factor-alpha from the oxyntic region and ulcer site during duodenal ulcer healing with ranitidine or sucralfate. J Int Med Res 1998; 26(2): 82-86.
55. Nexø E, Poulsen SS. Does epidermal growth factor play a role in the action of sucralfate? Scand J Gastroenterol 1987; 127 (Suppl): 45-49.
56. Konturek SJ, Brzozowski T, Majka J, et al. Fibroblast growth factor in gastroprotection and ulcer healing: Interaction with sucralfate. Gut 1993; 34(7): 881-887.
57. Konturek SJ, Brozozowski T, Bielanski W, Warzecha Z, Drozdowicz D. Epidermal growth factor in the gastroprotective and ulcer-healing actions of sucralfate in rats. Am J Med 1989; 86(6A): 32-37.
58. Lobb RR. Clinical applications of heparin-binding growth factors. Eur J Clin Invest 1988; 18(4): 321-336.
59. Slomiany BL, Piotrowski J, Slomiany A. Susceptibility of growth factors to degradation by Helicobacter pylori protease: Effect of ebrotidine and sucralfate. Biochem Mol Biol Int 1996; 40(1): 209-215.
60. Hu YL, Guo SZ, Lu KH. The effect of bFGF and sucralfate on cell proliferation during continuous tissue expansion. Zhonghua Zheng Xing Wai Ke Za Zhi 2003; 19(3): 203-206.
61. Nicaeus TE, Tolentino MJ, Adamis AP, Rubin PA. Sucralfate and basic fibroblast growth factor promote endothelial cell proliferation around porous alloplastic implants in vitro. Ophthal Plast Reconstr Surg 1996; 12(4): 235-239.
62. Loughman MS, Chatzistefanou K, Gonzalez EM, et al. Experimental corneal neovascularisation using sucralfate and basic fibroblast growth factor. Aust N Z J Ophthalmol 1996; 24(3): 289-295.
63. Konturek PC, Konturek SJ, Brzozowski T, Ernst H. Epidermal growth factor and transforming growth factor-alpha: Role in protection and healing of gastric mucosal lesions. Eur J Gastroenterol Hepatol 1995; 7(10): 933-937.
64. Tarnawski AS, Jones MK. The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: Involvement of EGF-R signal transduction pathways. J Clin Gastroenterol 1998; 27 (Suppl 1): S12-20.
65. Itoh M, Imai S, Joh T, et al. Effect of epidermal growth factor in combination with sucralfate or omeprazole on the healing of chronic gastric ulcers in the rat. J Clin Gastroenterol 1990; 12 (Suppl 1): S187-191.
66. Slomiany BL, Liu J, Keogh JP, Piotrowski J, Slomiany A. Enhancement of gastric mucosal epidermal growth factor and platelet-derived growth factor receptor expression by sucralfate. Gen Pharmacol 1992; 23(4): 715-718.
67. Zhang T, O'Keefe SJ, Winter T, Marks IN, Ogden J. Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-alpha, bFGF, and EGF receptor expression in humans. Dig Dis Sci 1998; 43(12): 2764-2770.
68. Liu J, Slomiany A, Slomiany BL. Effect of sucralfate on gastric mucosal calcium channels activity. Gen Pharmacol 1992; 23(6): 1129-1133.
69. Mannari C, Santi S, Migliori M, et al. Sucralfate modulates uPAR and EGFR expression in an experimental rat model of cervicitis. Int J Immunopathol Pharmacol 2008; 21(3): 651-658.
70. Robert A, Nezamis JE, Lancaster C, Hanchar AJ. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 1979; 77(3): 433-443.
71. Kamiyama M, Pozzi A, Yang L, DeBusk LM, Breyer RM, Lin PC. EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene 2006; 25: 7019-7028.
72. Bei R, Masuelli L, Turriziani M, Li Volti G, Malaguarnera M, Galvano F. Impaired expression and function of signaling pathway enzymes by anthocyanins: Role on cancer prevention and progression. Curr Enzyme Inhib 2009; [In press].
73. Eligini S, Arenaz I, Barbieri SS, Faleri ML, Crisci M, Tremoli E, Colli S. Cyclooxygenase-2 mediates hydrogen peroxide-induced wound repair in human endothelial cells. Free Radic Biol Med 2009; 46(10): 1428-1436.
74. Guo JS, Cho C, Lam LES, Coi HT, Wang JY, Leung KMW. Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats. Toxicol Appl Pharmacol 2002; 183: 41-45.
75. Hatazawa R, Tanaka A, Tanigami M, et al. Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors. Am J Physiol Gastrointest Liver Physiol 2007; 293(4): G788-797.
76. Sandulache VC, Parekh A, Li-Korotky HS, Dohar JE, Hebda PA. Prostaglandin E2 differentially modulates human fetal and adult dermal fibroblast migration and contraction: Implication for wound healing. Wound Repair Regen 2006; 14(5): 633-643.
77. Stenson WF. Prostaglandins and epithelial response to injury. Curr Opin Gastroenterol 2007; 23(2): 107-110.
78. Payno A, Lopez-Novoa JM, Rodriguez-Puyol D. Prostanoid production in post-gastrectomy gastritis. Influence of sucralfate. Am J Med 1989; 86(6A): 17-20.
79. Stern AI, Ward F, Hartley G. Protective effect of sucralfate against aspirin-induced damage to the human gastric mucosa. Am J Med 1987; 83(3B): 83-85.
80. Konturek SJ, Brzozowski T, Majka J, Czarnobilski K. Role of nitric oxide and prostaglandins in sucralfate-induced gastro-protection. Eur J Pharmacol 1992; 211(2): 277-279.
81. Slomiany BL, Murty VL, Piotrowski E, Morita M, Piotrowski J, Slomiany A. Activation of arachidonoyl phospholipase A2 in prostaglandin-mediated action of sucralfate. Gen Pharmacol 1994; 25(2): 261-266.
82. Coleman JC, Lacz JP, Browne RK, Drees DT. Effects of sucralfate or mild irritants on experimental gastritis and prostaglandin production. Am J Med 1987; 83(3B): 24-30.
83. Szelenyi I, Lanz R. Release of cytoprotective PGE2 from cultured macrophages induced by antacids and sucralfate. Agents Actions 1986; 18(3-4): 375-380.
84. Shindo K, Iizuka M, Sasaki K, et al. Sucralfate prevents the delay of wound repair in intestinal epithelial cells by hydrogen peroxide through NF-kappaB pathway. J Gastroenterol 2006; 41(5): 450-461.
85. Burch RM, McMillan BA. Sucralfate induces proliferation of dermal fibroblasts and keratinocytes in culture and granulation tissue formation in full-thickness skin wounds. Agents Actions 1991; 34(1-2): 229-231.
86. Greenhalgh DG. The role of apoptosis in wound healing. Int J Biochem Cell Biol 1998; 30(9): 1019-1030.
87. Matsuu-Matsuyama M, Shichijo K, Okaichi K, et al. Sucralfate protects intestinal epithelial cells from radiation-induced apoptosis in rats. J Radiat Res (Tokyo) 2006; 47(1): 1-8.
88. Hoshino T, Takano T, Tomisato W, et al. Effects of sucralfate on gastric irritant-induced necrosis and apoptosis in cultured guinea pig gastric mucosal cells. Biol Pharm Bull 2003; 26(1): 24-27.
89. Slomiany BL, Piotrowski J, Slomiany A. Gastric mucosal inflammatory responses toHelicobacter pylori lipopolysaccharide: Suppression of caspase-3 and nitric oxide synthase-2 by omeprazole and sucralfate. Inflammopharmacology 1999; 7(2): 163-177.
90. Slomiany BL, Piotrowski J, Slomiany A. Role of caspase-3 and nitric oxide synthase-2 in gastric mucosal injury induced by indomethacin: Effect of sucralfate. J Physiol Pharmacol 1999; 50(1): 3-16.
91. Slomiany BL, Piotrowski J, Slomiany A. Role of interleukin-4 in down-regulation of endothelin-1 during gastric ulcer healing: Effect of sucralfate. J Physiol Pharmacol 2000; 51(1): 69-83.
92. Slomiany BL, Piotrowski J, Slomiany A. Cell cycle progression during gastric ulcer healing by ebrotidine and sucralfate. Gen Pharmacol 1997; 29(3): 367-370.
93. Sencan A, Yilmaz O, Ozer E, et al. Does sucralfate prevent apoptosis occurring in the ischemia/reperfusion-induced intestinal injury? Eur J Pediatr Surg 2003; 13(4): 231-235.
94. Watanabe S, Wang XE, Hirose M, Osada T, Tanaka H, Sato N. Rebamipide prevented delay of wound repair induced by hydrogen peroxide and suppressed apoptosis of gastric epithelial cells in vitro. Dig Dis Sci 1998; 43 (Suppl 9): S107-112.
95. Wada K, Kamisaki Y, Kitano M, Kishimoto Y, Nakamoto K, Itoh T. Effects of sucralfate on acute gastric mucosal injury and gastric ulcer induced by ischemia-reperfusion in rats. Pharmacology 1997; 54(2): 57-63.
96. Slomiany BL, Piotrowski J, Majka J, Slomiany A. Sucralfate affects the susceptibility of Helicobacter pylori to antimicrobial agents. Scand J Gastroenterol 1995; (Suppl 210): 82-84.
97. Slomiany BL, Piotrowski J, Slomiany A. Effect of sucralfate on gastric mucosal inflammatory responses induced by Helicobacter pylori lipopolysaccharide. Scand J Gastroenterol 1998; 33(9): 916-922.
98. Bragman SG, Pankhurst CL, Casewell MW. Activity of sucralfate (sucrose octa-sulphate), an anti-ulcer agent, against opportunistic gram-negative bacilli. J Antimicrob Chemother 1995; 36(4): 703-706.
99. Bergmans D, Bonten M, Gaillard C, van Tiel F, van der Geest S, Stobberingh E. in vitro Antibacterial activity of sucralfate. Eur J Clin Microbiol Infect Dis 1994; 13(7): 615-620.
100. West AP, Abdul S, Sherratt MJ, Inglis TJ. Antibacterial activity of sucralfate against Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa in batch and continuous culture. Eur J Clin Microbiol Infect Dis 1993; 12(11): 869-871.
101. Tryba M, Mantey-Stiers F. Antibacterial activity of sucralfate in human gastric juice. Am J Med 1987; 83(3B): 125-127.
102. Kappstein I, Engels I. Antibacterial activity of sucralfate and bismuth subsalicylate in simulated gastric fluid. Eur J Clin Microbiol 1987; 6(2): 216-217.
103. Slomiany BL, Piotrowski J, Slomiany A. Suppression of Helicobacter pylori urease activity by sucralfate and sulglycotide. Biochem Mol Biol Int 1997; 42(1): 155-161.
104. Gianotti L, Alexander JW, Fukushima R, Pyles T. Reduction of bacterial translocation with oral fibroblast growth factor and sucralfate. Am J Surg 1993; 165(1): 195-200.
105. Packman, E. W.: US5478814 (1995).
106. Packman, E. W.: US5196405 (1993).
107. Packman, E. W.: US4945084 (1990).
108. Packman, E. W.: WO89000047 (1989).
109. Pehrson, D. W. Sr., Romanowsky, M. P.: WO91004034 (1991).
110. Kashimura, K., Ozawa, K.: US5968906 (1999).
111. Bar-shalom, D.K., Bukh, N.: US5618798 (1997).
112. Wharton, M. M.: US6194455 (1999).
113. Bar-shalom, D. K., Bukh, N., Hamburger, J.: US5240710 (1993).
114. Fogel, B. S.: US6159944 (2000).
115. Wharton, M. M.: US6838480 (2005).
116. Wharton, M. M.: US5908836 (2005).
117. Wharton, M. M.: US6372786 (2002).
118. Waddington, T. A.: US20090068128A1 (2009).
119. Yanagawa, A.: US5457128 (1995).
120. Michaeli, D.: US4912093 (1990).
121. Michaeli, D.: EP19860117762 (1992).
122. Conte, U., Colombo, P., Zagnoli, G., Caramella, C.: US5246697 (1993).
123. Cullen, B. M., Silcock, D. W., Warrick, J.: US20050159695A1 (2005).
124. Watt, P. W., Gregory, S. J., Trotter, P. J., Del Bono, M., Cullen, B. M., Lowing, P. H., Silcock, D, W., Marsden, D.C.: US20070225663A1 (2007).
125. Trotter, P. J., Culten, B. M.: US20080166397A1 (2008).
126. Packman, E. W.: US20050287096A1 (2005).
127. Folkman, M. J., Shing, Y.: US5202311 (1993).
128. Bar-shalom, D., Bukh, N.: US5908836 (1999).
129. Bar-shalom, D., Bukh, N.: US5916880 (1999).
130. Florine, D. L., Smith, T. J.: US5102870 (1992).
131. Fleming, T. E.: US20040039042A1 (2004).